WuXi XDC Cayman Inc. (HKG:2268)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
57.65
+1.65 (2.95%)
At close: Mar 5, 2026
81.00%
Market Cap 72.52B
Revenue (ttm) 5.58B
Net Income (ttm) 1.45B
Shares Out 1.26B
EPS (ttm) 1.12
PE Ratio 51.55
Forward PE 34.21
Dividend n/a
Ex-Dividend Date n/a
Volume 5,957,281
Average Volume 4,631,476
Open 57.30
Previous Close 56.00
Day's Range 56.10 - 58.35
52-Week Range 24.70 - 85.50
Beta -2.10
RSI 38.69
Earnings Date Mar 23, 2026

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Lab... [Read more]

Sector Healthcare
Founded 2013
Employees 2,270
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2268
Full Company Profile

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.